

As a result of the distrust of psychological approaches, studies of CBT (e.g. Kuipers *et al*, 1997; Sensky *et al*, 2000) have invariably recruited patients whose symptoms are 'resistant' to medication. The fact that these studies have still shown significant improvement over either a control intervention or routine care is testament to the greater benefits that might be demonstrated if the patients enrolled in research were representative of those in clinical practice targeted for psychological intervention.

In any case, surely the question is not which is more effective, but how both pharmacological and psychological approaches could be combined for greatest effect.

#### Declaration of interest

The author has received grants from the Wolfson Foundation and the Association of Physicians of Great Britain and Northern Ireland for research into the durability of cognitive-behavioural therapy for the treatment of schizophrenia.

**Gabbard, G. O. (2000)** A neurobiologically informed perspective on psychotherapy. *British Journal of Psychiatry*, **177**, 117–122.

**Kuipers, E., Garety, P., Fowler, D., et al (1997)** London–East Anglia randomised controlled trial of cognitive-behavioural therapy for psychosis: I. Effects of the treatment phase. *British Journal of Psychiatry*, **171**, 319–327.

**McKenna, P. J. (2003)** In debate: Is cognitive-behavioural therapy a worthwhile treatment for psychosis (against)? *British Journal of Psychiatry*, **182**, 477–479.

**Sensky, T., Turkington, D., Kingdon, D., et al (2000)** A randomized controlled trial of cognitive-behavioural therapy for persistent symptoms in schizophrenia resistant to medication. *Archives of General Psychiatry*, **57**, 165–172.

**N. Samarasekera** North Tyneside Hospital, Rake Lane, North Shields, Tyne and Wear NE29 8NH, UK

Thank you for the debate on CBT and schizophrenia (Turkington/McKenna, 2003). I would like to make the following points.

First, CBT is not a single treatment – it contains many complex components and skills, and therapist variables must be an essential issue for careful evaluation as with all psychological therapies.

Second, befriending fares significantly better than 'treatment as usual' in much CBT research. McKenna dismisses this as placebo or 'special treatment'. The fact of such significant improvement from

befriending says something very serious about treatment as usual. Why should those suffering from psychosis *not* receive special treatment? The finding points to the need for more consideration of the (poorly termed) 'non-specific factors in psychotherapy' – factors clearly not treated as sufficiently important in basic care in psychosis (Paley & Shapiro, 2002).

Third, in the Sensky *et al* (2000) trial quoted, CBT patients maintained their (significant) clinical improvement at follow-up, whereas the befriending controls fell back towards previous levels. It seems that CBT gives the patients a thinking structure to help manage some of their symptoms in the longer term.

Fourth, many people believe that you cannot treat persons with psychosis as if they were suffering from something such as diabetes, for which a single remedy like insulin might be sufficient. McKenna's pronouncement on randomised controlled trials is, therefore, open to serious questioning. The need adapted approach is the antithesis of the randomised controlled trial method. In the former, the treatment is individualised and intentionally different (qualitatively and quantitatively) from one case to another and may well change over time. A randomised controlled trial, equally intentionally, eliminates individuality in the treatment. Because the idea of relationships can be especially disturbing to patients with psychosis, psychological therapies can be seen by patients as threatening; therefore, the therapy has to be very carefully 'administered' – individually and flexibly.

Fifth, there are other outcome measurements at least as important as psychiatric symptoms. The experience of treatment is very important, as well as quality of life measurements. Turkington emphasises the high take-up rate of CBT, far higher than uptake of medication in psychosis.

Sixth, thank goodness for CBT, just one of several ways for practitioners to re-discover some tools that enable them to relate to patients with psychosis. McCabe *et al* (2002) show how uncomfortable ordinary psychiatrists are without such tools when engaging with patients when the latter want to discuss symptoms.

Seventh, CBT and psychodynamic approaches overlap to a degree, at least as practised by Turkington (Martindale, 1998; Turkington & Siddle, 1998). Much has changed in psychodynamic therapy since the flawed studies of old. Modern psychodynamic approaches to psychosis

have a much more flexible technique in engaging patients, and a greater and broader appreciation of mental mechanisms in psychosis.

Finally, relationship approaches in psychosis need encouragement, support and research. All psychiatrists need basic training in engaging with patients with psychosis. Research indicates that befriending might be a good place to start, but it is clearly not so easy – as the outcome of 'treatment as usual' indicates.

#### Declaration of interest

B.M. is Chair of ISPS (International Society for the Psychological Treatments of Schizophrenia) UK, a network the main objective of which is to promote psychological approaches to psychosis (treatment, education and research).

**Martindale, B. (1998)** Commentary (on Cognitive therapy for the treatment of delusions). *Advances in Psychiatric Treatment*, **4**, 241–242.

**McCabe, R., Heath, C., Burns, T. (2002)** Engagement of patients with psychosis in the consultation: conversation analytic study. *BMJ*, **325**, 1148–1151.

**Paley, A. & Shapiro, A. (2002)** Lessons from psychotherapy research for psychological interventions for people with schizophrenia. *Psychology and Psychotherapy: Theory, Research and Practice*, **75**, 5–17.

**Sensky, T., Turkington, D., Kingdon, D., et al (2000)** A randomized controlled trial of cognitive-behavioural therapy for persistent symptoms in schizophrenia resistant to medication. *Archives of General Psychiatry*, **57**, 165–172.

**Turkington, D., Siddle, R. (1998)** Cognitive therapy for the treatment of delusions. *Advances in Psychiatric Treatment*, **4**, 235–241.

— / **McKenna, P. (2003)** In debate: Is cognitive-behavioural therapy a worthwhile treatment for psychosis? *British Journal of Psychiatry*, **182**, 477–479.

**B. Martindale** Psychotherapy Department, John Conolly Wing, West London Mental Health NHS Trust, Uxbridge Road, Southall UBI 3EU, UK

#### Efficacy of antidepressant medication

The debate between Parker and Anderson & Haddad (2003) neatly summarised contemporary thinking on the question of antidepressant effect. It was a pity, though, that they provided no discussion of any historical perspective. The wonderfully clear account provided by David Healy (2002), for instance, shows how the marketing tail of psychopharmaceuticals now often wags the entire dog. The process by which this came about has been gathering momentum since the early 1960s. Healy explores its various causes and corollaries